Ignite Creation Date:
2025-12-24 @ 4:47 PM
Ignite Modification Date:
2025-12-25 @ 2:33 PM
Study NCT ID:
NCT06637150
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-10-15
First Post:
2024-09-28
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Dalpicilib-Enhanced Vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer
Sponsor:
Fudan University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-09-01
Start Date Type:
ACTUAL
Primary Completion Date:
2030-09-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-09-30
Completion Date Type:
ESTIMATED
First Submit Date:
2024-09-28
First Submit QC Date:
None
Study First Post Date:
2024-10-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-09
Last Update Post Date:
2024-10-15
Last Update Post Date Type:
ACTUAL